ClinicalTrials.Veeva

Menu

Cognitive Functions After COVID-19

M

Medipol University

Status

Completed

Conditions

COVID-19 Acute Respiratory Distress Syndrome
Cognitive Decline

Treatments

Behavioral: Neuropsychometric Test

Study type

Observational

Funder types

Other

Identifiers

NCT04978246
Medipol Mega3

Details and patient eligibility

About

This study was aimed to evaluate the post-infection cognitive functions of adult individuals with COVID-19. 50 individuals with COVID-19 and 50 healthy control groups were included in the study. Cognitive functions of individuals with COVID19 compared with healthy individuals.

Full description

This study was aimed to evaluate the post-infection cognitive functions of adult individuals with COVID-19. Fifty COVID-19 patients, aged between 18-50 years, who had positive RT-PCR test in the last 60 days and later recovered, were included in the study. The study group was compared with the control group consisting of 50 healthy individuals in whom gender, age and education year has not difference significantly. Participants' global cognitive skills were measured by the Montreal Cognitive Assessment Test (MoCA), the Clock Drawing Test and memory functions, the Öktem Verbal Memory Processes Test (Ö-SBST), the attention functions by the Digit Span Forward and Digit Span Backwards Test, the executive functions by Categorical Fluency, Phonemic Fluency, the Stroop Test, Trail Making Test A and B, visuospatial skills were evaluated with the Rey-Osterrieth Complex Figure Test (ROCF), and behavioral symptoms were evaluated with the Neuropsychiatric Inventory (NPI). The study group was evaluated between 21 and 60 days from the onset of the disease.

Enrollment

100 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Having positive for the COVID-19 RT-PCR test and turned negative in the last 60 days.
  • be 18-50 years old
  • 21 days have passed since the onset of the disease

Exclusion criteria

  • Having any neurological or psychiatric illness

Trial design

100 participants in 2 patient groups

Study Group
Description:
The study group consists of 50 individuals aged 18-50 years who have received a positive COVID-19 RT-PCR test in the past 60 days.
Treatment:
Behavioral: Neuropsychometric Test
Control Group
Description:
The control group consists of 50 healthy individuals aged 18-50 years who have not had COVID-19.
Treatment:
Behavioral: Neuropsychometric Test

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems